66 Results

People

  1. Shah
    Shah
  2. Mailankody
    Mailankody
  3. Giralt
    Giralt
  4. Lesokhin
    Lesokhin
  5. Shah
    Shah
  6. Derkach
    Derkach
  7. Hassoun
    Hassoun
  8. Korde
    Korde
  9. Tan
    Tan
  10. Landau
    Landau

Groups

  1. Bone Marrow Transplant (66)
  2. Center for Hematologic Malignancies (66)
  3. Department of Medicine (66)
  4. Hematologic Malignancies Research (66)
  5. Hematologic Malignancies, Division of (66)
  6. Population Sciences Research Program (66)
  7. Survivorship Research (64)
  8. Epidemiology and Biostatistics (60)
  9. Sloan Kettering Institute Postdocs (60)
  10. Biostatistics Service (55)
  1. "Hematologic Malignancies Research"
  2. "Center for Hematologic Malignancies"
  3. "Bone Marrow Transplant"
  4. "Population Sciences Research Program"
Formats
  1. Meeting Abstract (53)
  2. Journal Article (10)
  3. Research Letter (2)
  4. Correspondence (1)
Groups
  1. Bone Marrow Transplant (66)
  2. Center for Hematologic Malignancies (66)
  3. Department of Medicine (66)
  4. Hematologic Malignancies Research (66)
  5. Hematologic Malignancies, Division of (66)
  6. Population Sciences Research Program (66)

More Groups

People
  1. Gunjan Shah (51)
  2. Malin Hultcrantz (49)
  3. Sham Mailankody (49)
  4. Alexander Lesokhin (48)
  5. Sergio Giralt (48)
  6. Urvi Shah (48)

More People

Years
  1. 2023 (18)
  2. 2022 (18)
  3. 2021 (10)
  4. 2020 (6)
  5. 2019 (4)
  6. 2018 (2)

More Years

Publications
  1. Blood (32)
  2. Clinical Lymphoma, Myeloma and Leukemia (13)
  3. Journal of Clinical Oncology (5)
  4. American Journal of Hematology (2)
  5. Biology of Blood and Marrow Transplantation (2)
  6. Blood Cancer Journal (2)

More Publications

Publishers
  1. American Society of Hematology (32)
  2. Elsevier Inc. (16)
  3. American Society of Clinical Oncology (5)
  4. Nature Publishing Group (3)
  5. American Association for Cancer Research (2)
  6. Elsevier Science, Inc. (2)

More Publishers

Results (66)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Responses and outcomes after second-line therapy in transplant-eligible patients with DLBCL relapse over 1 year after first-line therapy
    Meeting Abstract

    Qualls, D. A.; Shah, G. L.; Shouval, R.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) and daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C.; Maclachlan, K. H.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Patel, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • T-cell exhaustion signature predicts early relapse after autologous stem cell transplant for multiple myeloma: BMT CTN 0702 secondary immune analysis
    Meeting Abstract

    Mehanna, N.; Derkach, A.; Gasmi, B.; Anagnostou, T.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Hassoun, H.; Maclachlan, K. H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Comprehensive genomic characterization of response and resistance to daratumumab-based quadruplet induction in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Maclachlan, K. H.; Tan, C. R.; Shekarkhand, T.; Rueda, C.; Serrano, E.; Nemirovsky, D.; Derkach, A.; McPherson, A.; Diamond, B.; Ziccheddu, B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A whole foods plant-based weight loss intervention improves quality of life, metabolic, microbiome and immune profile in MGUS/SMM as well as progression trajectory in a subset - the Nutrivention trial
    Meeting Abstract

    Shah, U. A.; Castro, F.; Derkach, A.; Fei, T.; Hosszu, K. K.; McAvoy, D.; DeWolf, S.; Cross, J.; Gradissimo, A.; Nwankwo, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Carfilzomib,lenalidomide and dexamethasone (KRd) as induction therapy in high-risk newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C.; Korde, N.; Derkach, A.; Hultcrantz, M.; Maclachlan, K. H.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Patel, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Evaluating the effect of evolving changes in serum biomarkers on the risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Nemirovsky, D.; Maclachlan, K. H.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U. A.; Tan, C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A comparative analysis of infectious complications in patients with multiple myeloma treated with BCMA-targeted bispecific antibodies and CAR T-cell therapy
    Meeting Abstract

    Nath, K.; Shekarkhand, T.; Costa, B. A.; Nemirovsky, D.; Derkach, A.; Nishimura, N.; Farzana, T.; Rueda, C.; Chung, D.; Landau, H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clinical outcomes associated with del(17p) in newly diagnosed multiple myeloma treated with triplet and daratumumab-based quadruplet induction regimens
    Meeting Abstract

    Jurgens, E.; Firestone, R.; Maclachlan, K. H.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A whole foods plant-based weight loss intervention improves metabolic and immune biomarkers in MGUS/SMM patients as well as progression trajectory in a subset: The NUTRIVENTION trial
    Meeting Abstract

    Shah, U.; Derkach, A.; Castro, F.; Anuraj, A.; Blaslov, J.; Hosszu, K.; Pollak, M.; Mailankody, S.; Korde, N.; Tan, C. R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save